|Quality Indicator Sets For Scleroderma|
|Wednesday, 21 September 2011 12:02|
Despite the increasing awareness of Scleroderma (SSc), it continues to have a detrimental effect of the quality of health and lives of those with it. The medical community has recognized that although early treatment of Scleroderma can have a substantial effect on outcomes, no studies of the quality of care had been done.
Similarly, Quality Indicators (QI) had already been established for health care in arthritis, gout, rheumatologic prescribing, and systemic lupus erythematosus - but none for the treatment of Scleroderma (SSc). Earlier this year, a set of quality indicators for Scleroderma were published by some of the top Scleroderma researchers. These indicators were meant to represent measurable, minimum standards of care that should be applied to all patients with Scleroderma.
These researchers chose to develop these measures because the processes of care tended to be under the control of the health care provider or health system and are more efﬁciently measured than the outcomes. Additionally, it would have allowed for the identification of speciﬁc areas of care that were deﬁcient and could have been targeted for quality improvement.
The Indicators covers nine essential areas: Cardiopulmonary, Pulmonary, Gastrointestinal, Renal, Musculoskeletal, Cutaneous, Health-Related Quality of Life, Serologies, and Prevention and Drug Monitoring. 32 Quality Indicators were developed: 9 for those newly diagnosed with Scleroderma, 12 follow-up indicators for its management, and 11 for treatment. A few were highlighted below;
To read the full article from Clinical and Experimental Rheumatology, we would like to encourage you to visit the following link. You can also read the previous article we posted earlier this year. We encourage you to also print out a copy for reference and to share with your medical practitioner or doctor.